Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes. Issue 12 (13th October 2020)

• Record Type: Journal Article
• Authors: Paramathas, Sangeetha; Guha, Tanya; Pugh, Trevor J.; Malkin, David; Villani, Anita
• Is Part Of: Pediatric blood & cancer. Volume 67:Issue 12(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-10-13
• Subjects: cancer predisposition syndrome -- circulating tumor DNA -- early detection -- hereditary cancer -- liquid biopsies -- surveillance; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28758
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Liquid biopsy, specifically circulating tumor DNA (ctDNA) detection, has started to revolutionize the clinical management of patients with cancer by surpassing many limitations of traditional tissue biopsies, particularly for serial testing. ctDNA sequencing has been successfully utilized for cancer detection, prognostication, and assessment of disease response and evolution. While the applications of ctDNA analysis are growing, the majority of studies to date have primarily evaluated its use as a tool for tracking a known cancer, and in most cases at advanced stage. Herein, we discuss the potential application of ctDNA for surveillance and early cancer detection in patients with a cancer predisposition syndrome.